Adjunctive Cariprazine Shifts More MDD Patients Into Lower Severity Categories
This post hoc analysis of a phase 3 adjunctive cariprazine trial translates mean Montgomery-Åsberg Depression Rating Scale (MADRS) changes into severity-category shifts and response-history subgroups, which matters for pharmacists advising on augmentation after inadequate antidepressant response.
Cariprazine shows promise in boosting depression treatment efficacy.
Many patients with major depressive disorder (MDD) do not achieve adequate symptom relief with antidepressants alone, necessitating effective adjunctive treatments. Adjunctive cariprazine improved depressive symptom severity categories more than placebo, with 68% showing at least a one-category improvement. As a post hoc analysis, the findings support cariprazine's potential as an adjunctive treatment, but further studies are needed for definitive conclusions. Cariprazine may enhance symptom improvement for MDD patients insufficiently managed on antidepressants alone.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Masand PS, Chen C, Adams JL, Kramer K, Kerolous M
Citation:Masand PS, Chen C, Adams JL, et al. Categorical Improvement in Depressive Symptom Severity: Results From a Randomized Controlled Trial of Cariprazine for Adjunctive Treatment of MDD. CNS spectrums. 2023;28(2):245. doi:10.1017/S1092852923001803